(1888PressRelease)
June 03, 2009 - The seven-year note was priced at 99.757% and has a maturity date of June 15, 2016. It is guaranteed by Novartis AG, which is incorporated in Switzerland and is the ultimate parent company of Novartis Finance S.A., Luxembourg, the issuing entity.
This offering was met with considerable interest, reflected by the fact it was oversubscribed more than four times and was placed to a diversified and international investor base.
Novartis AG is rated Aa2 (stable outlook) by Moody's, AA- (stable outlook) by Standard & Poor's and AA (stable outlook) by Fitch. Barclays, BNP Paribas and Deutsche Bank were joint book-runners.
About Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff ( @ ) novartis dot com
###
